Raymond James & Associates Kaleido Biosciences, Inc. Transaction History

Raymond James & Associates

  • $150 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021
SELL
$5.82 - $8.72 $591,021 - $885,516
-101,550 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$7.2 - $16.82 $731,160 - $1.71 Million
101,550 New
101,550 $823,000

About Kaleido Biosciences, Inc.

KLDO Quotes by TradingView
  • Ticker KLDO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,622,600
  • Description
  • Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...
More about KLDO
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email